BioNTech SE - American Depositary Shares (NQ:BNTX)

BNTX ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against BioNTech SE (BNTX)

Topics Lawsuit

January 20, 2024

From Kessler Topaz Meltzer & Check, LLP

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX

January 20, 2024

WHY: NEW YORK, NY - (NewMediaWire) - January 20, 2024 - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of...

The Law Offices of Frank R. Cruz Announces Investigation of BioNTech SE (BNTX) on Behalf of Investors

Topics Lawsuit

P/E Ratio Insights for BioNTech ↗

January 09, 2024

Via Benzinga

Comparative Study: BioNTech And Industry Competitors In Biotechnology Industry ↗

January 03, 2024

Via Benzinga

How Is The Market Feeling About BioNTech? ↗

December 26, 2023

Via Benzinga

January 19, 2024

From The Law Offices of Frank R. Cruz

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages BioNTech SE Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BNTX

January 19, 2024

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX

Topics Lawsuit

January 18, 2024

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

BioNTech SE (BNTX) Shareholder Alert: Robbins LLP Reminds Investors of Class Action Filed Against BioNTech SE

Topics Lawsuit

Understanding BioNTech's Position In Biotechnology Industry Compared To Competitors ↗

December 20, 2023

Via Benzinga

January 18, 2024

From Robbins LLP

BIONTECH ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against BioNTech SE and Encourages Investors to Contact the Firm

January 17, 2024

From Bragar Eagel & Squire

BIONTECH SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioNTech To Contact Him Directly To Discuss Their Options

January 17, 2024

From Faruqi & Faruqi LLP

Jim Cramer Says Hold Onto This Biotech Stock: 'I Don't Understand Why It's So Inexpensive' ↗

January 17, 2024

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would back Moderna, Inc. (NASDAQ: MRNA) here.

Via Benzinga

BIONTECH SE SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against BioNTech SE (NASDAQ: BNTX)

January 16, 2024

From Bernstein Liebhard LLP

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages BioNTech SE Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – BNTX

January 16, 2024

From The Rosen Law Firm, P.A.

BNTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioNTech SE Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

January 15, 2024

From Bronstein, Gewirtz & Grossman, LLC

Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week ↗

January 13, 2024

Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will...

Via Talk Markets

BioNTech Prepares To Be Commercial Ready By 2025, Revenue Growth Expected To Return In 2025 ↗

January 09, 2024

On Tuesday, BioNTech SE (NASDAQ: BNTX) outlined priorities at the Annual J.P.

Via Benzinga

BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference

January 09, 2024

From BioNTech SE

Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Additionally, Allorion Therapeutics has out-licensed global rights (ex-China)...

Week In Review: 2024 Kicks Off With Three Deals Worth A Total Of $4 Billion ↗

January 07, 2024

Via Talk Markets

Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada ↗

January 05, 2024

The FDA has allowed Florida to import prescription drugs from Canada, potentially altering the landscape of how Americans access and afford their medications.

Via Benzinga

5 Value Stocks To Watch In The Healthcare Sector ↗

January 01, 2024

Via Benzinga

Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024 ↗

December 28, 2023

2024 will mark a pivotal moment for the healthcare industry, particularly in drug pricing negotiations.

Via Benzinga

A Look Into Healthcare Sector Value Stocks ↗

December 25, 2023

Via Benzinga

BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer

December 21, 2023

From BioNTech SE

COVAX Global Initiative For COVID-19 Vaccines Comes To An End Amid Shift To Regular Programs ↗

December 20, 2023

COVAX, the multilateral mechanism for equitable global access to COVID-19 vaccines launched in 2020, will close on 31 December 2023.&n

Via Benzinga

Why Is COVID-19 Vaccine Player CureVac Stock Plummeting Today? ↗

December 19, 2023

A German court has invalidated a patent central to CureVac N.V's (NASDAQ: CVAC) lawsuit against BioNTech SE (NASDAQ: BNTX) related to seeking fair compensation for infringement of a portfolio of

Via Benzinga

Topics Intellectual Property Lawsuit

BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda

December 18, 2023

From BioNTech SE